Ağrı Tedavisinde Adjuvan İlaçlar
Özet
Kronik ağrı, farklı patofizyolojik mekanizmaların rol oynadığı ve çoğu zaman multimodal tedavi yaklaşımı gerektiren kompleks bir klinik durumdur. Adjuvan analjezikler, primer endikasyonları ağrı tedavisi olmamasına rağmen farklı kronik ağrı sendromlarında analjezik etkinlik gösteren ve günümüzde ağrı yönetiminin önemli bileşenleri arasında yer alan ilaçlardır. Bu bölümde kronik ağrı tedavisinde kullanılan başlıca adjuvan ilaç grupları; antidepresanlar, antikonvülzanlar, kortikosteroidler, N-metil-D-aspartat (NMDA) reseptör antagonistleri, alfa-2 adrenerjik agonistler ve intravenöz lidokain başlıkları altında ele alınmaktadır. Bu ilaçların etki mekanizmaları, klinik kullanım alanları, etkinlikleri ve güvenlilik profilleri güncel literatür doğrultusunda değerlendirilmektedir. Ayrıca adjuvan ilaçların nöropatik ağrı, kanser ağrısı ve girişimsel ağrı tedavisindeki rolleri üzerinde durulmaktadır. Uygun hasta ve ilaç seçimiyle adjuvan tedavilerin multimodal ağrı yönetimine katkı sağlayabileceği, tedavinin ağrı mekanizması, komorbiditeler ve olası yan etkiler dikkate alınarak bireyselleştirilmesi gerektiği vurgulanmaktadır.
Chronic pain is a complex clinical condition involving multiple pathophysiological mechanisms and often requiring a multimodal treatment approach. Adjuvant analgesics are medications whose primary indications are not pain management but which provide analgesic efficacy in various chronic pain syndromes and have become important components of contemporary pain management. This chapter reviews the major classes of adjuvant drugs used in chronic pain treatment, including antidepressants, anticonvulsants, corticosteroids, N-methyl-D-aspartate (NMDA) receptor antagonists, alpha-2 adrenergic agonists, and intravenous lidocaine. Their mechanisms of action, clinical indications, efficacy, and safety profiles are discussed in the context of current literature. Particular attention is also given to the roles of adjuvant drugs in neuropathic pain, cancer pain, and interventional pain management. The chapter emphasizes that, with appropriate patient and drug selection, adjuvant therapies can contribute substantially to multimodal pain management and that treatment should be individualized according to the underlying pain mechanism, patient comorbidities, and potential adverse effects.
Referanslar
Treede RD, Rief W, Barke A, et al. Chronic pain as a symptom or a disease: The IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain. 2019;160(1):19-27.
International Association for the Study of Pain. IASP Terminology. Pain terms and definitions. Washington (DC): IASP; 2021.
Cohen SP, Vase L, Hooten WM. Chronic pain: An update on burden, best practices, and new advances. Lancet. 2021;397(10289):2082-2097.
World Health Organization. WHO guideline for the clinical management of chronic pain in adults. Geneva: World Health Organization; 2023. https://www.who.int/publications/i/item/9789240081789
Dworkin RH, O'Connor AB, Kent J, et al. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain. 2013;154(11):2249-2261.
Finnerup NB, Haroutounian S, Kamerman P, et al. Neuropathic pain: An updated grading system for research and clinical practice. Pain. 2016;157(8):1599-1606.
Raja SN, Carr DB, Cohen M, et al. The revised International Association for the Study of Pain definition of pain: Concepts, challenges, and compromises. Pain. 2020;161(9):1976-1982.
Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173.
Attal N, Cruccu G, Baron R, et al. EFNS guidelines on thepharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.
Finnerup NB, Kuner R, Jensen TS. Neuropathic pain: From mechanisms to treatment. Physiol Rev. 2021;101(1):259-301.
National Institute for Health and Care Excellence (NICE). Neuropathic pain in adults: pharmacological management in non-specialist settings. NICE Guideline No. 173. London: National Institute for Health and Care Excellence; 2020. https://www.nice.org.uk/guidance/cg173
Sindrup SH, Otto M, Finnerup NB,et al. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol. 2005;96(6):399-409.
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;(4):CD005454.
Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain and fibromyalgia. Cochrane Database Syst Rev. 2014;(1):CD007115.
Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy. JAMA. 2013;309(13):1359-1367.
Moore RA, Derry S, Aldington D, et al. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;(7):CD008242.
Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain. 2007;132(3):237-251.
Moulin DE, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328-335.
Jensen TS, Baron R, Haanpää M, et al. A new definition of neuropathic pain. Pain. 2011;152(10):2204-2205.
Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD007938.
Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin: Calcium channel α2δ ligands. Pain. 2009;142(1-2):13-16.
Cruccu G, Finnerup NB, Jensen TS, et al. Trigeminal neuralgia: New classification and diagnostic grading for practice and research. Neurology. 2016;87(2):220-228.
Bendtsen L, Zakrzewska JM, Heinskou TB, et al. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. Lancet Neurol. 2020;19(9):784-796.
Gronseth G, Cruccu G, Alksne J, et al. Practice Parameter: The diagnostic evaluation and treatment of trigeminal neuralgia. Neurology. 2008;71(15):1183-1190.
Zaccara G, Giovannelli F, Giorgi FS, et al. Tolerability of new antiepileptic drugs: A network meta-analysis. CNS Drugs. 2013;27(9):759-776.
Baron R, Binder A, Wasner G. Neuropathic pain: Diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807-819.
Wiffen PJ, Derry S, Moore RA. Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2013;(12):CD006044.
Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2013;(11):CD010567.
Knezevic NN, Jovanovic F, Voronov D,et al. Do corticosteroids still have a place in the treatment of chronic pain? Front Pharmacol. 2018;9:1229.
Cohen SP, Bicket MC, Jamison D,et al. Epidural steroids: a comprehensive, evidence-based review. Reg Anesth Pain Med. 2013;38(3):175-200.
Kennedy DJ, Plastaras CT, Casey E, et al. Comparative effectiveness of lumbar transforaminal epidural steroid injections with particulate versus nonparticulate corticosteroids for lumbar radicular pain due to intervertebral disc herniation. Pain Med. 2014;15(4):548-555.
Rathmell JP, Benzon HT, Dreyfuss P, et al. Safeguards to prevent neurologic complications after epidural steroid injections. Anesthesiology. 2015;122(5):974-984.
Kim D, Brown J. Efficacy and safety of lumbar epidural dexamethasone versus methylprednisolone in the treatment of lumbar radiculopathy: a comparison of soluble versus particulate steroids. Clin J Pain. 2011;27(6):518-522.
Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv166-iv191.
Delaney FT, Pingree MJ, Smuck M,et al. An update on epidural steroid injections: is there still a role for particulate corticosteroids? Curr Opin Anaesthesiol. 2023;36(5):603-609.
Zhou HY, Chen SR, Pan HL. Targeting N-methyl-D-aspartate receptors for treatment of neuropathic pain. Expert Rev Clin Pharmacol. 2011;4(3):379-388.
Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 2014;77(2):357-367.
Yang Y, Maher DP, Cohen SP. Emerging concepts on the use of ketamine for chronic pain. Expert Rev Clin Pharmacol. 2020;13(2):135-146.
Cohen SP, Bhatia A, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain. Reg Anesth Pain Med. 2018;43(5):521-546.
Zhao J, Wang Y, Wang D. The effect of ketamine infusion in the treatment of complex regional pain syndrome: a systematic review and meta-analysis. Curr Pain Headache Rep. 2018;22(2):12.
Schwenk ES, Viscusi ER, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for acute pain management. Reg Anesth Pain Med. 2018;43(5):456-466.
Ferraro MC, Bell RF, Cooper TE, et al. Ketamine and other NMDA receptor antagonists for chronic pain. Cochrane Database Syst Rev. 2025.
Eisenach JC, De Kock M, Klimscha W. Alpha-2 adrenergic agonists for regional anesthesia: a clinical review. Anesthesiology. 1996;85(3):655-674.
Giovannitti JA Jr, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog. 2015;62(1):31-39.
Vorobeichik L, Brull R, Abdallah FW. Evidence basis for using perineural dexmedetomidine to enhance the quality of brachial plexus nerve blocks: a systematic review and meta-analysis of randomized controlled trials. Br J Anaesth. 2017;118(2):167-181.
Bahari Z, Meftahi GH. Spinal alpha-2 adrenoceptors and neuropathic pain modulation. Br J Pharmacol. 2019;176(14):2366-2381.
Abdallah FW, Dwyer T, Chan VW, et al. IV and perineural dexmedetomidine similarly prolong the duration of analgesia after interscalene brachial plexus block. Anesthesiology. 2016;124(3):683-695.
Albrecht E, Vorobeichik L, Jacot-Guillarmod A,et al. Dexamethasone is superior to dexmedetomidine as a perineural adjunct for supraclavicular brachial plexus block: systematic review and indirect meta-analysis. Anesth Analg. 2019;128:543-554.
Horvat S, Goren O, Vlainich R, et al. Intravenous lidocaine for treatment of chronic pain: a retrospective cohort study. J Pain Res. 2022;15:3721-3730.
Lee JH, Kim YC, Shin HY, et al. Intravenous lidocaine infusion for chronic neuropathic pain: a systematic review. Pain Physician. 2022;25:E821-E834.
Zhu B, Huang Y, Peng L, et al. Intra-venous lidocaine to relieve neuropathic pain: a systematic review and meta-analysis. Front Neurol. 2019;10:954.
van der Wal SEI, van den Heuvel SAS, Radema SA, et al. Intravenous lidocaine for chronic peripheral neuropathic pain: a randomized placebo-controlled trial. Pain Med. 2019;20:655-664.
Neal JM, Barrington MJ, Fettiplace MR, et al. The Third American Society of Regional Anesthesia and Pain Medicine Practice Advisory on Local Anesthetic Systemic Toxicity: Executive Summary 2023. Reg Anesth Pain Med. 2023;48:113-124.
World Health Organization. WHO guideline for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. Geneva: World Health Organization; 2023. https://www.who.int/publications/i/item/9789241550390
Sohi G, Lao N, Caraceni A, et al. Nonopioid drug combinations for cancer pain: a systematic review. PAIN. 2022;163(3):e282-e293.
